Home

*Recorded during the live 2008 AAAAI/ACAAI Certification/Maintenance of Certification Board Review Course, April 16-19, 2008.

Welcome

The 2008-2009 AAAAI/ACAAI Certification/Maintenance of Certification Online Board Review Course

Programmed by the AAAAI. Funded though an educational grant from Teva Specialty Pharmaceuticals.

Accreditation Statement:
The American Academy of Allergy, Asthma & Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education credits for physicians.

Designation Statement:
The American Academy of Allergy, Asthma & Immunology (AAAAI) designates this educational activity for a maximum of 29.25 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in this activity.

AAAAI Privacy Policy:
To verify your participation in online educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at cme@aaaai.org

Target Audience:
Allergy and immunology physicians and FITs preparing to take the 2008 ABAI certification and maintenance of certification exams. Allergists and immunologists seeking a literature review. Physicians who have completed their training but have never taken the ABAI exam.

Medium and Method of Physician Participation:
The AAAAI/ACAAI Certification/Maintenance of Certification Board Review Course consists of recordings of sessions presented during the live course which took place April 16-19, 2008 in Chicago, Illinois. To complete this activity:

1. Review the target audience, learning objectives and disclosures
2. View the individual sessions, as well as the syllabus materials and review questions for each session.
3. For each unit of the course, complete the activity evaluation.

Learning Objectives:
Upon completion of this activity, participants will be able to:

• Identify, evaluate, and manage the current problems and issues in allergy and immunology in preparation for the ABAI examination.

AAAAI Disclosure Policy:
Pursuant to the Code of Ethics for the American Academy of Allergy, Asthma & Immunology (AAAAI) and the Standards for Commercial Support of Continuing Medical Education of the Accreditation Council for Continuing Medical Education, the AAAAI requires disclosure of certain information from faculty members of educational activities designated for CME credit by the AAAAI. Prior to the activity, faculty members are required to disclose all relationships that meet the following parameters:

1. Employment. Name of employer and job title.
2. Financial interests. All organizations, other than the employer, from which the faculty member or a member of his/her immediate family or household receives annual remuneration in any amount (including grants, honoraria and consulting fees).
3. Research interests. All organizations which support research projects for which the faculty member or member of his/her immediate family or household serves as an investigator.
4. Organizational interests. All organizations, other than the AAAAI, for which the faculty member holds volunteer positions.
5. Gifts. All organizations from which the faculty member or a member of his/her immediate family or household have received a gift of any amount in the last year.
6. Other interests. All interests of the faculty member or a member of his/her immediate family or household that would be judged by a majority of his/her peers to be more than casual and/or likely to impact his/her ability to exercise independent judgment. This includes any financial interest in or relationship with any manufacturer of a commercial product, and any financial interest or relationship with any organization that provides commercial support to AAAAI-sponsored educational activities.

The information disclosed by the design committee and faculty members of this activity is reported below for the review and information of activity participants.

Design Committee and Faculty Members and their Disclosures:

Emil J. Bardana, Jr., MD A. Employment: Oregon Health and Science University; B. Financial Interests: Nothing to disclose; C. Research Interests: Nothing to disclose; D. Organizational Interests: Nothing to disclose; E. Gifts: Nothing to disclose; F. Other: Pfizer: Consultant/lecturer; Aventis: Consultant/lecturer

Melvin Berger, MD PhD A. Employment: Case Western Reserve University School of Medicine (University Hospitals Medical Group): Professor of Pediatrics and Pathology); B. Financial Interests: FFF Enterprises, Grifols Biologics Inc., Talecris Biotherapeutics: Consulting fees and/or honoraria; CSL Behring: Consulting fees, speaking fees, and honoraria; C. Research Interests: Talecris Biotherapeutics, Baxter: Grants; D. Organizational Interests: Immune Deficiency Foundation: Medical Advisory Committee; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Mark Boguniewicz, MD A. Employment: National Jewish Medical Research Center: Professor B. Financial Interests: Novartis: Research grants, lecture honoraria; Fujisawa (Astellas): Research grants, lecture honoraria; C. Research Interests: Sinclair: Research grant; Fujisawa (Astellas): Research grants; Novartis: Research grants; Graceway Pharmaceuticals: Consulting; Shire: Consulting; D. Organizational Interests: ACAAI: Member; E. Gifts: Nothing to disclose; F. Other: Novartis: Lecture honoraria; Fujisawa (Astellas): Lecture honoraria

Larry Borish, MD A. Employment: University of Virginia Health Care Systems: Professor in Medicine B. Financial Interests: Merck: Speaker’s bureau; Genentech, Sepracor, Protein Design Labs, Inc., Critical Therapeutics, Syngenta, Isis Pharmaceuticals: Consultant; C. Research Interests: National Institutes of Health, GlaxoSmithKline: Grantee; D. Organizational Interests: ACAAI, AAAAI: Committee; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

David D. Chaplin, MD PhD A. Employment: University of Alabama at Birmingham: Professor and Department Chair; B. Financial Interests: Nothing to disclose; C. Research Interests: National Institutes of Health: Principal investigator for NIH funded research; National Science Foundation: Principal Investigator; D. Organizational Interests: Nothing to disclose; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Stephen C. Dreskin, MD PhD A. Employment: University of Colorado School of Medicine: Professor of Medicine and Immunology; B. Financial Interests: Nothing to disclose; C. Research Interests: Food Allergy and Anaphylaxis Network: Grant support; National Institutes of Health: Grant support D. Organizational Interests: Colorado Allergy Society: Board member; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Thomas A. Fleisher, MD A. Employment: National Institutes of Health, DHHS: Chief, Department of Laboratory Medicine; B. Financial Interests: Nothing to disclose; C. Research Interests: Nothing to disclose; D. Organizational Interests: Clinical Immunology Society: Past President; Robert A. Good Immunology Society: President; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Michael M. Frank, MD A. Employment: Duke University Medical Center: Professor of Pediatrics, Medicine and Immunology; B. Financial Interests: Dyax, Jerini, Lev Pharma, CSL Behring, Pharming: All of the 5 companies above are attempting to develop therapy for Hereditary Angioedema. I consult for all of them on study design and help with clinical trial set up. For Dyax I am on the Data Safety Monitoring Board. I have received a grant in aid from Lev and CSL Behring; C. Research Interests: Lev Pharma and CSL Behring: I have received a grant in aid for research from these two companies; D. Organizational Interests: Nothing to disclose; E. Gifts: Nothing to disclose; F. Other: I am the advisory board of a number of companies attempting to develop therapy for Hereditary Angioedema – See financial

Paul A. Greenberger, MD A. Employment: Northwestern University Feinberg School of Medicine: Professor of Medicine; B. Financial Interests: Novartis: Consultant (Adjudication committee); Genentech: Consultant; C. Research Interests: National Heart, Lung, and Blood Institute: Research support; D. Organizational Interests: Nothing to disclose; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Daniel L. Hamilos, MD A. Employment: Massachusetts General Hospital: Associate Professor of Medicine; B. Financial Interests: Merck, Genentech, Critical Therapeutics: Speaker honoraria C. Research Interests: FAMRI, Novartis, GlaxoSmithKline, Sepracor, Genentech: Research grants or studies; D. Organizational Interests: Schering, Genentech, Sinexus, Dey LP, ISIS, Novartis, Accentia: Consultant; E. Gifts: G.G. Monks Foundation: Monetary gifts to purchase lab equipment; F. Other: Nothing to disclose

Steven M. Holland, MD A. Employment: The National Institutes of Health: Chief, Laboratory of Clinical Infectious Diseases; B. Financial Interests: Nothing to disclose; C. Research Interests: Nothing to disclose D. Organizational Interests: International Immunocompromised Host Society: President; Clinical Immunology Society: Elected counselor; USIDNET: Steering committee; Primary Immune Deficiency Foundation: Board ; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Arthur F. Kavanaugh, MD A. Employment: University of California-San Diego: Professor of Medicine; B. Financial Interests: Nothing to disclose; C. Research Interests: Amgen: Research studies; D. Organizational Interests: American College of Rheumatology: Communications committee; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

David A. Khan, MD A. Employment: University of Texas SW Medical Center: Associate Professor of Internal Medicine; B. Financial Interests: Merck: Speaker’s bureau; Novartis: Speaker’s bureau; C. Research Interests: AstraZeneca: Research grant; Jerini: Research support; D. Organizational Interests: Texas Allergy, Asthma & Immunology Society: President; JCAAI: Member of Joint Task Force on Practice Parameters; ACAAI: Co-chair Conjoint Board Review Committee, Co-chair, Allied Health Symposium Committee; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Amy D. Klion, MD A. Employment: National Institutes of Health: Staff physician; B. Financial Interests: Nothing to disclose; C. Research Interests: Nothing to disclose; D. Organizational Interests: Nothing to disclose; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Carol A. Langford, MD MHS A. Employment: Cleveland Clinic: Director, Center for Vasculitis Care and Research; B. Financial Interests: Nothing to disclose; C. Research Interests: Bristol Meyers Squibb: Provides study drug for a clinical trial in which I am an investigator; Genentech: Provides study drug for a clinical trial in which I am an investigator; D. Organizational Interests: American College of Rheumatology: Professional Meeting Committee; Continuous Professional Development Committee; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Tao Le, MD A. Employment: Medsn, Inc: Consultant; GSK: Speaker’s bureau; Sanofi-aventis: Speaker’s bureau; B. Financial Interests: Nothing to disclose; C. Research Interests: University of California San Francisco: Research consultant; D. Organizational Interests: ACAAI: Member, CME Committee; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Dennis K. Ledford, MD A. Employment: University of South Florida College of Medicine and James A. Haley VA Hospital: Professor of Medicine and Pediatrics; B. Financial Interests: Merck: Speaker bureau honoraria; Genentech: Consultant and speaker bureau honoraria; Novartis: Consultant and speaker honoraria; MedPointe: Speaker bureau with honoraria; Sanofi-aventis: Consultant and speaker bureau with honoraria; Critical Therapeutics: Speaker bureau with honoraria; C. Research Interests: GlaxoSmithKline: Clinical trial; Genentech: Clinical trial; Novartis: Clinical trial; Novartis: Clinical trial; Sanofi Aventis: Clinical COPD trial; AstraZeneca: Clinical trial; D. Organizational Interests: American College of Allergy, Asthma & Immunology: Member, Active committee member, Contributing Editor Allergy Watch; American College of Physicians: Volunteer editor; American Medical Association: Member; Journal of Allergy and Clinical Immunology: Associate editor; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Kristin M. Leiferman, MD A. Employment: University UT Health Science Center: Professor of Dermatology, Co-Director of Immunodermatology Laboratory; B. Financial Interests: Jerini, Dyax: Spouse has grant; Ception: Spouse has stock; Genentech: Spouse is a speaker and received honoraria; Novartis: Spouse is a speaker, received honoraria and research grant; Beiersdorf: Dermatology Advisory Panel; Immunodermatology Laboratory, University of Utah: Co-director; GlaxoSmithKline: Consultant and research grant, spouse is a consultant, has received honoraria and research grant; C. Research Interests: NIH: Husband is a PI on two grants; WHO (World Health Organization): Husband is an investigator on an expired grant; D. Organizational Interests: National Eczema Association: Scientific Advisory Committee; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Robert F. Lemanske, Jr., MD A. Employment: University of Wisconsin School of Medicine and Public Health: Professor of Pediatrics and Medicine; B. Financial Interests: Merck, GlaxoSmithKline, AstraZeneca: Speaker honoraria/consultant; Novartis/Genentech: Consultant; Aventis: Consultant; C. Research Interests: National Heart, Lung, and Blood Institute: Provide extramural support for University-based clinical and basic science research projects; National Institute of Allergy and Infectious Disease: Provide extramural support for research projects; D. Organizational Interests: Nothing to disclose; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Phillip L. Lieberman, MD A. Employment: Allergy and Asthma Associates: Partner; B. Financial Interests: Sanofi-Aventis: Speakers bureau and/or consultant; Verus: Speakers bureau and/or consultant; Dey: Speakers bureau and/or consultant; Merck: Speakers bureau and/or consultant; MedPointe: Speakers bureau and/or consultant; Genentech: Speakers bureau and/or consultant; Novartis: Speakers bureau and/or consultant; Inspire: Speakers bureau and/or consultant; Schering: Speakers bureau and/or consultant; Astra Zeneca: Speakers bureau and/or consultant; C. Research Interests: Nothing to disclose; D. Organizational Interests: Food Allergy and Anaphylaxis Network: Grant review ; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Kathleen R. May, MD A. Employment: Private Practice in Appalacia, IRB: Vice Chair of the Local Hospital system in IRB; B. Financial Interests: Nothing to disclose; C. Research Interests: Nothing to disclose; D. Organizational Interests: Nothing to disclose; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Harold S. Nelson, MD A. Employment: National Jewish Medical Research Center: Professor of Medicine B. Financial Interests: Genentech: Consulting, grants; Novartis: Consulting, grants; Schering-Plough: Consulting, grants; Dey Laboratories: Consulting, grants; Dynavax Tech Laboratories: Consulting, grants; Curalesic: Consulting, grants; Abbott Laboratories: Consulting, grants; Medici Nova: Consulting, grants; GlaxoSmithKline: Consulting, grants, speaker’s bureau; AstraZeneca: Consulting, grants; TEVA: Consulting, grants; C. Research Interests: Critical Therapeutic: Grants; Wyeth: Grants; Altma: Grants; Behringer: Grants; Sepracor: Grants; D. Organizational Interests: Nothing to disclose; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Anna H. Nowak-Wegrzyn, MD A. Employment: Mount Sinai School of Medicine: Assistant Professor of Pediatrics; B. Financial Interests: Nothing to disclose; C. Research Interests: Nothing to disclose D. Organizational Interests: New York Allergy and Asthma Society: Executive committee member; E. Gifts: Nothing to disclose; F. Other: Novartis: Nothing to disclose

Jordan Orange, MD PhD A. Employment: Children’s Hospital of Philadelphia: Assistant Professor; B. Financial Interests: CSL Behring: consultancy, speakers bureau; Baxter: consultancy; C. Research Interests: NIH: Research grant; AAAAI ERT: Career development award; D. Organizational Interests: Clinical Immunology Society: Membership committee; Immune Deficiency Foundation: Medical Advisory Council; US Immunodeficiency Network: Advisory committee; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Dennis R. Ownby, MD A. Employment: Medical College of Georgia: Professor of Pediatrics/Internal Medicine; B. Financial Interests: Genentech: Consulting; CR Bard: Consulting ; C. Research Interests: National Institutes of Allergy and Infectious Diseases: Investigator on grants; D. Organizational Interests: National Institutes of Allergy and Infectious Diseases: Data-safety Monitoring Board; National Institutes of Health: Member of IRAP Study Section; American Academy of Pediatrics: Member of the National Conference and Exhibition Planning Committee; Merck Childhood Asthma Network: Member, Board of Directors; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

John M. Routes, MD A. Employment: Medical College of Wisconsin/Children’s Hospital of Wisconsin: Professor; B. Financial Interests: Nothing to disclose; C. Research Interests: Nothing to disclose; D. Organizational Interests: Nothing to disclose; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Harry W. Schroeder, MD PhD A. Employment: The University of Alabama at Birmingham: Professor; B. Financial Interests: The National Institutes of Health: Review – NIH Grants; The Journal of Immunology: Section Editor; C. Research Interests: The National Institutes of Health: Grantee – Principal Investigator on NIH Gratns; USIDnet: Grantee – Principal investigator; NABI: Grantee – Investigator; D. Organizational Interests: Nothing to disclose; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Lawrence B. Schwartz, MD PhD A. Employment: Virginia Commonwealth University: Professor of Medicine; B. Financial Interests: Pharmacia Diagnostics: royalties that are receieved by VCU for sales of the tryptase immunoassay are, in part, passed on to me; Merck: honoraria to spouse; GlaxoSmithKline: honoraria to spouse; Genentech/Novartis: honoraria to spouse; Sanofi Aventis: consultant honoraria, honoraria to spouse; AstraZeneca: honoraria to spouse; NIH: honoraria for study section service; Genentech/Novartis: consultant advisory board honoraria, speaker honoraria; Astra Zeneca: honoraria to spouse; NIH: honoraria for study section service; Genentech/Novartis: consultant advisory board honoraria, speaker honoraria; C. Research Interests: Genentech: Research grant to study FcERI expressioin; NIH: Research grants to study mast cells and basophils; Wyeth Pharmaceutical Co: Development of an in vitro test for allergic sensitivity to biologics; Philip Morris: Researcg grant to study human lung mast cells; King Pharmaceutical Co: Clinical trial, A2a agonist; Genentech: Research contract to measure tryptase levels in Xolair-treated patients; D. Organizational Interests: Nothing to disclose; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

William T. Shearer, MD PhD A. Employment: Texas Children’s Hospital: Professor of pediatric immunology; B. Financial Interests: Nothing to disclose; C. Research Interests: National Institutes of Health, National Institute of Allergy and Infectious Diseases: Principal investigator on research projects; National Institutes of Health, National Institute of Child Health and Development: Principal investigator on research projects; National Institutes of Health, National Institute of Heart, Lung, and Blood Institute: Principal investigator on research projects; National Aeronautics and Space Administration, National Space Biomedical Research Institute: Principal investigator on research project; National Institutes of Health, National Center for Complementary and Alternative Medicine: Co-investigator on research project; D. Organizational Interests: Houston, Chair, Regional Cabinet, Washington University in St. Louis: Fundraising ; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Charles J. Siegel, MD: A. Employment: University of Missouri at Kansas City School of Medicine, Allergy/Asthma Specialists of Kansas City: Associate Clinical Professor, Dept. of Peds., Practicing allergist; B. Financial Interests: MedPointe: consultation; Verus: consultation; GlaxoSmithKline: speaker; Merck: speaker; Schering: speaker; Sanofi-aventis: speaker; UCB: speaker; TEVA: speaker; AstraZeneca: speaker; C. Research Interests: Nothing to disclose; D. Organizational Interests: Nothing to disclose; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

John W. Sleasman, MD A. Employment: University of South Florida: Professor and Division Chief B. Financial Interests: CSL Behring: Consultant; C. Research Interests: National Institutes of Health: Principal investigator; National Oceanic and Atmospheric Administration: Principal investigator D. Organizational Interests: Elizabeth Glaser Pediatric AIDS Foundation: Advisor; All Children’s Hospital: Advisor; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

John W. Steinke, PhD A. Employment: University of Virginia: Assistant Professor; B. Financial Interests: Current topics in asthma and allergy: In the past two years I have received two $100 checks for reviews I was asked to write; C. Research Interests: NIH, Richmond Eye and Ear: I am co-investigator on the Allergic Disease Center grant awarded to our institution, and R01 awarded to Larry Borish and a Richmond Eye and Ear grant awarded to Joe Hahn; D. Organizational Interests: Nothing to disclose; E. Gifts: Nothing to disclose; F. Other: Nothing to disclose

Richard W. Weber, MD A. Employment: National Jewish Medical and Research Center: Professor of Medicine; B. Financial Interests: Genentech: Speaker’s bureau; GlaxoSmithKline: Speaker’s bureau; Aventis: Speaker’s bureau; Novartis: Speaker’s bureau; C. Research Interests: GlaxoSmithKline: Research grant; Eli Lilley: Research grant; Pfizer: Research grant; Mannkind: Research grant; D. Organizational Interests: ACAAI: Committee chair; E. Gifts: Nothing to disclose; F. Other: Novartis: Nothing to disclose

Release date:
June 15, 2008. Valid for credit through March 31, 2010.

Questions:
Activity-related questions should be directed to cme@aaaai.org